Aurobindo Pharma has supported the PEPFAR program since its inception by filing HIV drugs with the US Food and Drug Administration (USFDA) for tentative approval to supply to low- and middle-income countries (LMIC). Through the PEPFAR program, Aurobindo Pharma can reach out to people living with HIV (PLHIV) and deliver drugs at more affordable prices. Aurobindo Pharma was the first generic company to develop dolutegravir and has also developed the combination of tenofovir and lamivudine (“TLD”), before launching the USFDA approved product in LMICs. Today, Aurobindo Pharma has significantly scaled up its capacity and is able to supply treatment to 3-4 million patients globally.
Over the years, Aurobindo Pharma has actively worked to adapt and improve our outreach initiatives, incorporating feedback from many different stakeholders. We continue to closely monitor our efforts to reach as many patients as possible, to fulfil our commitment to healthier life.
We Believe
No child should be born with HIV. No child should be an orphan because of HIV. No one should die due to lack of access to treatment.
© Copyright 2025 Aurobindo Pharma Limited. All rights reserved.